Incidence of Malignancy after Living Kidney Transplantation: A Multicenter Study from Iran

Einollahi, Behzad; Rahimi, Zohreh; Nourbala, Mohammad Hossein; Lessan‐Pezeshki, Mahboob; Simforoosh, N.; Nemati, Eghlim; Pourfarziani, Vahid; Beiraghdar, Fatemeh; Nafar, Mohsen; Pour-Reza-Gholi, Fatemeh; Mazdeh, M Mahdavi; Amini, Manochehr; Pedram, Ahmadpour; Makhdoomi, Khadijeh; Ghafari, A.; Ardalan, Mohammadreza; Khosroshahi, Hamid T.; Oliaei, Farshid; Shahidi, Shahrzad; Abbaszadeh, Shahin; Fatahi, R.; Hiedari, Fatemeh; Makhlogh, Atehieh; Azmandian, Jalal; Samimagham, Hamid Reza; Shahbazian, Heshmatollah; Nazemian, Fatemeh; Naghibi, Massih; Khosravi, Masoud; Monfared, Ali Shabestani; Mosavi, Seyed Majid; Ahmadi, Jamshid; Jalalzadeh, Mojgan

doi:10.7150/jca.3042

Cited by 16 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Squamous cell carcinoma of the skin is the most common malignancy and affected patients have a five-fold increased risk of developing another solid tumor ( 31 ). In European population, posttransplant lymphoproliferative disorders (PTLD) are the second most common malignancies and the same features were founded in a report from Iran ( 32 - 34 ). Geographic distribution of human herpes virus type-8 and Epstein-Bar virus (EBV) infections are important risk factors for Kaposi sarcoma and PTLD development, respectively ( 33 , 34 ).…”

Section: Resultsmentioning

confidence: 70%

Global Scientific Vision With Local Vigilance: Renal Transplantation in Developing Countries

Ardalan

2014

Nephro Urol Mon

Self Cite

View full text Add to dashboard Cite

Context:Renal Transplantation is the most effective treatment for patients with end-stage renal disease, which is fortunately available in the developing countries, even for poor people. Nonetheless, the way forward should be the implementation of advanced science of transplantation, allograft monitoring abilities, knowledge about the epidemiology of renal disease in any specific region, awareness about the influence of ethenic and genetic factors immunosuppressant bioavailability, and post-transplant complications all strongly affecting the patients and allograft survival.Evidence Acquisitions:In this process we searched mainly in PubMed, Web of Science and Google Scholar data bases for key words of renal allograft monitoring, post-transplant infections, renal/kidney transplantation and Iran. We followed the cross articles to follow our main idea to find a connection between modern advancement in renal allograft monitoring and our practice in developing countries. Another focus was on the special infectious and non-infection complication that do exist in specific region and need specific considerations.Results:Implementation of modern techniques of immune monitoring, allograft function, awareness about the specific infectious and non-infectious disease in each region improves the quality of renal transplantation.Conclusions:We need to combine the advance scientific vision with local vigilance to achieve the best outcome in renal allograft recipients

show abstract

Section: Resultsmentioning

confidence: 70%

Global Scientific Vision With Local Vigilance: Renal Transplantation in Developing Countries

Ardalan

2014

Nephro Urol Mon

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that the immune surveillance plays a fundamental role in the pathogenesis of melanoma (4), as confirmed by the importance of immunotherapeutic approach in the treatment of advanced stages of this disease (9). However, while data concerning the higher risk of NMSC after transplantation are well established (2, 3, 10), not all authors agree about the increase in melanoma risk in transplant recipients (1,(6)(7)(8)(9)(10)(11)(12).…”

Section: Discussionmentioning

confidence: 99%

Melanoma Risk in Renal Transplanted Patients

et al. 2017

View full text Add to dashboard Cite

Despite the well-known increased risk to develop non-melanoma skin cancer (NMSC) due to the long-term immunosuppression, data about melanoma incidence and prognosis in solid organ transplanted patients are still debated. Literature studies report a relative risk for melanoma varying from 1.2 and 5.8 in different solid organ recipients, probably as a consequence of the difference in immunosuppressive treatments and endogenous and exogenous risk factors. Here we report data about melanoma incidence, prognosis and clinicopathological characteristics in a series of 686 kidney transplant recipients. In this series, melanoma incidence was 3.5%; most cases were represented by in situ or thin melanomas mainly related to sun exposure, and the prognosis of our patients was good except for only one case with a progressive disease. Our experience confirms the importance of a regular dermatological follow-up and of education to correct sun exposure even in transplanted patients.

show abstract

“…Although immunosuppressive therapy has successfully reduced the risk of rejection after kidney transplantation, more aggressive immunosuppression has increased the occurrence of malignancy and PTLD 1 , 2 , 14 . Renal transplant recipients with PTLD have been managed with a variety of approaches including reduction in immunosuppression, antiviral therapy, surgical resection, chemotherapy, radiation and cellular therapy 2 , 3 .…”

Section: Discussionmentioning

confidence: 99%

“…Immunosuppressive therapy in kidney transplant recipients have successfully reduced the risk of rejection after kidney transplantation, however, malignancy and post-transplant lymphoproliferative disorder (PTLD) are common complications of immunosuppressive therapy 1 – 5 .…”

Section: Introductionmentioning

confidence: 99%

Outcome Of Rapamycin Therapy For Post Transplant- Lymphoproliferative Disorder After Kidney Transplantation: Case Series

Ashrafi

Shahidi

Ebrahimi

et al. 2013

Blood

Self Cite

View full text Add to dashboard Cite

Background Post transplant lymphoproliferative disorders (PTLD) , are a complication of chronic immunosuppressive therapy in solid organ transplantation with a high mortality rate. Alternative treatments such as rapamycin have been explored. Methods A detailed retrospective analysis was performed according to data collected from thirteen patients with PTLD. At the time of PTLD diagnosis, immunosuppressive therapy was decreased and rapamycin administered. Overall survival and disease free survival of patients and graft survival were determined. Results Among 590 kidney transplant recipients, thirteen adult patients with PTLD were included in this study. The mean age of the patients was 42.15 (range: 25-58) years at the time of PTLD diagnosis, and 9 patients were male. Histology was distributed in 9 diffuse large B cell, 1 Malt lymphoma, 1 Burkitt lymphoma, 2 Hodgkin-like PTLD. The response rate to rapamycin alone was 30.8%. The mean overall survival period is 27.4 months with 9 patients still living. In total, 10 patients (76.9%) achieved a complete remission, with functioning graft in 11 (84.6%) patients. Conclusions Despite to retrospective and limited number of patients, this study provides promising results regarding the effectiveness of stopping calcineurin inhibitors and switching to rapamycin for patients with PTLD. Disclosures: No relevant conflicts of interest to declare.

show abstract

Incidence of Malignancy after Living Kidney Transplantation: A Multicenter Study from Iran

Cited by 16 publications

References 39 publications

Global Scientific Vision With Local Vigilance: Renal Transplantation in Developing Countries

Global Scientific Vision With Local Vigilance: Renal Transplantation in Developing Countries

Melanoma Risk in Renal Transplanted Patients

Outcome Of Rapamycin Therapy For Post Transplant- Lymphoproliferative Disorder After Kidney Transplantation: Case Series

Contact Info

Product

Resources

About